Combined Treatment of Treated Bile Duct Cancer
Condition: Bile Duct Cancer Intervention: Drug: envolizumab , sovalteinib Sponsor: Zhejiang Cancer Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 22, 2023 Category: Research Source Type: clinical trials
Pemigatinib Combined With PD-1 Inhibitor in Unresectable or Metastatic Intrahepatic Cholangiocarcinoma
Conditions: Carcinoma; Intrahepatic Cholangiocarcinoma; Digestive System Neoplasms; PD-1 Inhibitor; First-line Treatment Interventions: Drug: Pemigatinib; Drug: PD-1 Inhibitors Sponsors: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University; First Affiliated Hospital of Jinan University; Shenzhen University General Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 22, 2023 Category: Research Source Type: clinical trials
Combined Treatment of Treated Bile Duct Cancer
Condition: Bile Duct Cancer Intervention: Drug: envolizumab , sovalteinib Sponsor: Zhejiang Cancer Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 22, 2023 Category: Research Source Type: clinical trials
Pemigatinib Combined With PD-1 Inhibitor in Unresectable or Metastatic Intrahepatic Cholangiocarcinoma
Conditions: Carcinoma; Intrahepatic Cholangiocarcinoma; Digestive System Neoplasms; PD-1 Inhibitor; First-line Treatment Interventions: Drug: Pemigatinib; Drug: PD-1 Inhibitors Sponsors: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University; First Affiliated Hospital of Jinan University; Shenzhen University General Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 22, 2023 Category: Research Source Type: clinical trials
Combined Treatment of Treated Bile Duct Cancer
Condition: Bile Duct Cancer Intervention: Drug: envolizumab , sovalteinib Sponsor: Zhejiang Cancer Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 22, 2023 Category: Research Source Type: clinical trials
Pemigatinib Combined With PD-1 Inhibitor in Unresectable or Metastatic Intrahepatic Cholangiocarcinoma
Conditions: Carcinoma; Intrahepatic Cholangiocarcinoma; Digestive System Neoplasms; PD-1 Inhibitor; First-line Treatment Interventions: Drug: Pemigatinib; Drug: PD-1 Inhibitors Sponsors: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University; First Affiliated Hospital of Jinan University; Shenzhen University General Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 22, 2023 Category: Research Source Type: clinical trials
Combined Treatment of Treated Bile Duct Cancer
Condition: Bile Duct Cancer Intervention: Drug: envolizumab , sovalteinib Sponsor: Zhejiang Cancer Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 22, 2023 Category: Research Source Type: clinical trials
Pemigatinib Combined With PD-1 Inhibitor in Unresectable or Metastatic Intrahepatic Cholangiocarcinoma
Conditions: Carcinoma; Intrahepatic Cholangiocarcinoma; Digestive System Neoplasms; PD-1 Inhibitor; First-line Treatment Interventions: Drug: Pemigatinib; Drug: PD-1 Inhibitors Sponsors: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University; First Affiliated Hospital of Jinan University; Shenzhen University General Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 22, 2023 Category: Research Source Type: clinical trials
Combined Treatment of Treated Bile Duct Cancer
Condition: Bile Duct Cancer Intervention: Drug: envolizumab , sovalteinib Sponsor: Zhejiang Cancer Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 22, 2023 Category: Research Source Type: clinical trials
Pemigatinib Combined With PD-1 Inhibitor in Unresectable or Metastatic Intrahepatic Cholangiocarcinoma
Conditions: Carcinoma; Intrahepatic Cholangiocarcinoma; Digestive System Neoplasms; PD-1 Inhibitor; First-line Treatment Interventions: Drug: Pemigatinib; Drug: PD-1 Inhibitors Sponsors: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University; First Affiliated Hospital of Jinan University; Shenzhen University General Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 22, 2023 Category: Research Source Type: clinical trials
The Construction of Clinical Database and Multiomics Biobank Based on a Multicentral Prospective Cohort of Benign and Malignant Biliary Tract Diseases
Conditions: Biliary Tract Diseases; Gallbladder Cancer; Extrahepatic Bile Duct Cancer; Intrahepatic Cholangiocarcinoma; Biliary Tract Neoplasms; Gall Stone Intervention: Other: no interventions Sponsor: RenJi Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 9, 2023 Category: Research Source Type: clinical trials
